Temferon shows consistent survival metrics in glioblastoma patients with unmethylated MGMT, with 44% reaching 18-month ...

This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and ...

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes ...

Unfortunately, there are no currently available data or guidelines to support the safe de-escalation or cessation of ...

In an interview with Targeted Oncology ®, Stefania Morganti, MD, PhD, research fellow at the Dana-Farber Cancer Institute, ...

VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...